Study guide
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD
Key Takeaways Explain This Topic AI
Cardiovascular aging is characterized by arterial stiffening, left ventricular diastolic dysfunction (impaired relaxation), increased reliance on sinus rhythm and atrial kick (up to 20-30% of LV end-diastolic volume), and blunted beta-adrenergic receptor responsiveness.
Respiratory changes include loss of pulmonary elastic recoil, increased lung compliance, and stiffening of the chest wall; Closing Capacity (CC) increases progressively, exceeding FRC in the supine position at ~44 years and in the upright position at ~66 years, leading to ventilation-perfusion mismatch and age-related decline in PaO₂ (PaO₂ ≈ 100 - [0.3 × Age]).
Central nervous system changes feature brain atrophy, loss of neurotransmitter synthesis, and a 6-7% decrease in volatile anesthetic Minimum Alveolar Concentration (MAC) per decade after age 40 (approximating a ~30% reduction by age 80).
Renal GFR and blood flow decline by approximately 1 mL/min/year after age 40; serum creatinine remains deceptively normal due to concurrent loss of skeletal muscle mass, necessitating calculated creatinine clearance for drug dosing.
Postoperative Delirium (POD) is an acute, fluctuating disturbance of attention and cognition presenting in the early postoperative period (evaluated via CAM-ICU), whereas Postoperative Cognitive Dysfunction (POCD) is a subtle, persistent decline in memory and executive function detected by formal neuropsychometric testing weeks to months later; Beers Criteria mandates avoiding high-risk medications including benzodiazepines, diphenhydramine, meperidine, and tertiary amine anticholinergics.
Last updated: August 2026
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD
The geriatric surgical demographic is expanding rapidly, presenting anesthesia providers with unique physiological, pharmacological, and cognitive vulnerabilities. Aging is characterized by a progressive reduction in physiological functional reserve across all organ systems, altered body composition, diminished homeostatic adaptability, and heightened susceptibility to perioperative neurocognitive disorders.
1. Cardiovascular Aging Physiology & Hemodynamics
Cardiovascular alterations in the elderly are driven primarily by structural remodeling of large elastic arteries and the left ventricle, combined with autonomic dysregulation. +---------------------------------------------------------------------------------------------------------+
- | GERIATRIC CARDIOVASCULAR ALTERATIONS |
- +-----------------------+--------------------------------------+------------------------------------------+
- | Physiological Entity | Structural / Functional Alteration | Clinical Anesthetic Implication |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Vascular Tree** | • Loss of elastin & increased col- | • Elevated systolic BP, widened pulse |
- | | lagen in arterial media | pressure, increased SVR |
- | | • Decreased arterial compliance | • Elevated afterload → concentric LVH |
- | | • Increased Pulse Wave Velocity | • Exaggerated hypotension upon induction |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Left Ventricle** | • Concentric hypertrophy & fibrosis | • Impaired active myocardial relaxation |
- | | • **Diastolic Dysfunction (impaired | • Critical dependence on **atrial kick** |
- | | early passive diastolic filling)** | • Tachycardia & Afib cause flash edema |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Autonomic System** | • Decreased β-adrenergic receptor | • Blunted max heart rate response to |
- | | density & uncoupling of Gs-proteins| hypovolemia, stress, or atropine |
- | | • Down-regulated baroreceptor reflex | • Severe postural / induction hypotension|
- | | • Elevated circulating catecholamines| • Decreased inotropic response to β-agon |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Conduction System** | • Fibrofatty infiltration of SA/AV | • High incidence of sick sinus syndrome, |
- | | nodes and bundle branches | bundle branch blocks, and 1st/2nd AVB |
- +-----------------------+--------------------------------------+------------------------------------------+
- Diastolic Dysfunction & The Critical "Atrial Kick"
In the young compliant heart, approximately 70 − 80 % 70 - 80\% 70 − 80% of left ventricular filling occurs during early rapid passive diastole (the E E E wave on Doppler echocardiography), with the remaining 20 − 30 % 20 - 30\% 20 − 30% contributed by atrial contraction (the A A A wave). In the stiff, non-compliant geriatric ventricle:
Early passive filling is significantly impaired ( E / A ratio < 1.0 E/A \text{ ratio } < 1.0 E / A ratio < 1.0 ).
The atrial contraction ("atrial kick") contributes up to 30 − 40 % 30 - 40\% 30 − 40% of total left ventricular end-diastolic volume (LVEDV).
Clinical Hazard: Sudden loss of sinus rhythm (e.g., new-onset atrial fibrillation or junctional rhythm) or severe tachycardia ( > 100 bpm >100 \text{ bpm} > 100 bpm , which severely truncates diastolic filling time) precipitously drops stroke volume, triggering profound systemic hypotension and acute pulmonary edema.
Blunted Beta-Adrenergic Responsiveness
While baseline circulating plasma norepinephrine levels are elevated in older adults due to enhanced sympathetic tone, post-receptor intracellular signaling is blunted:
Beta-1 and Beta-2 receptor density and affinity decrease, coupled with impaired adenylyl cyclase activation.
The maximum heart rate declines predictably with age, estimated by: Max Heart Rate ≈ 220 − Age \text{Max Heart Rate} \approx 220 - \text{Age} Max Heart Rate ≈ 220 − Age
Sympathetic baroreceptor buffering is sluggish. Induction agents that cause peripheral vasodilation (e.g., propofol) produce precipitous drops in Mean Arterial Pressure (MAP) without compensatory reflex tachycardia.
Direct-acting alpha-1 agonists (e.g., phenylephrine) or combined inotropes/vasopressors (e.g., norepinephrine, ephedrine) may be required in titrated doses to maintain coronary and cerebral perfusion.
2. Respiratory Aging Physiology & Gas Exchange +-------------------------------------------------------------------------+
- | GERIATRIC PULMONARY MECHANICS |
- +-------------------------------------------------------------------------+
- | • Loss of Lung Elastic Recoil (Lung Compliance INCREASES) |
- | • Calcification of Costochondral Cartilage (Chest Wall Compliance ↓) |
- | • Flattening & Atrophy of Diaphragmatic Muscle Fibers |
- | • Progressive Increase in Residual Volume (RV) & Closing Capacity (CC) |
- | • Functional Residual Capacity (FRC) Remains Relatively Constant/Slight ↑|
- | • Vital Capacity (VC) and FEV₁ DECREASE Progressively |
+-------------------------------------------------------------------------+ [CLOSING CAPACITY VS. FRC ACROSS THE LIFESPAN]
- Volume (L)
- ^
- | / Closing Capacity (CC)
- | /
- | -----------+----------------- FRC (Upright)
- | / | (CC > FRC Upright at ~66 yrs)
- | -----------+-------------+----------------- FRC (Supine)
- | / | (CC > FRC Supine at ~44 yrs)
- | / |
- | / |
- +--------------------+----------------------------------> Age (Years)
- 44 yrs 66 yrs
- Closing Volume (CV) & Closing Capacity (CC)
Closing Capacity ( C C = C V + R V CC = CV + RV CC = C V + R V ): The lung volume at which dependent terminal bronchioles begin to collapse during expiration.
Age-Related Intersection Points:
In the supine position, C C CC CC exceeds resting F R C FRC FRC at approximately 44 years 44 \text{ years} 44 years of age .
In the upright (standing) position, C C CC CC exceeds resting F R C FRC FRC at approximately 66 years 66 \text{ years} 66 years of age .
When C C > F R C CC > FRC CC > FRC , dependent airway closure occurs during normal tidal respiration, causing microatelectasis, intrapulmonary right-to-left shunting, and ventilation-perfusion ( V / Q V/Q V / Q ) mismatching.
Formula for Age-Related Decline in Arterial Oxygen Tension
Arterial oxygen tension ( P a O 2 PaO_2 P a O 2 ) declines progressively with age during room air breathing due to increasing V / Q V/Q V / Q inequality: P a O 2 ≈ 100 − ( 0.3 × Age ) or P a O 2 ≈ 102 − ( 0.33 × Age ) PaO_2 \approx 100 - (0.3 \times \text{Age}) \quad \text{or} \quad PaO_2 \approx 102 - (0.33 \times \text{Age}) P a O 2 ≈ 100 − ( 0.3 × Age ) or P a O 2 ≈ 102 − ( 0.33 × Age )
Example: An 80-year-old patient on room air has a predicted normal P a O 2 ≈ 100 − ( 0.3 × 80 ) = 76 mmHg PaO_2 \approx 100 - (0.3 \times 80) = 76 \text{ mmHg} P a O 2 ≈ 100 − ( 0.3 × 80 ) = 76 mmHg (compared to ≈ 95 mmHg \approx 95 \text{ mmHg} ≈ 95 mmHg in a 20-year-old).
Ventilatory Drive Reflexes
Central hypercapnic ventilatory response and peripheral hypoxic ventilatory response are blunted by up to 50 % 50\% 50% in elderly patients.
Geriatric patients exhibit heightened vulnerability to airway obstruction, hypercarbic respiratory failure, and severe hypoxemia under residual sedation, opioids, or volatile anesthetics.
3. Central & Peripheral Nervous System Aging +---------------------------------------------------------------------------------------------------------+
- | GERIATRIC NEUROLOGICAL ALTERATIONS |
- +-----------------------+--------------------------------------+------------------------------------------+
- | Neurological Domain | Structural / Biomolecular Change | Clinical Impact |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Brain Morphology** | • Loss of 10-20% cortical neurons | • Increased sensitivity to CNS depress- |
- | | • Decreased brain mass & white matter| ants (propofol, midazolam, opioids) |
- | | • Widened sulci & enlarged ventricles| • Increased free volume in dura/cranium |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Neurochemistry** | • Decreased acetylcholine synthesis | • Elevated baseline risk of delirium |
- | | • Decreased dopamine & serotonin | • Enhanced vulnerability to anticholinerg|
- | | • Decreased GABA-A receptor density | • Exaggerated sedative response |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Inhalational MAC** | • Decreased synaptic density and | • **MAC declines 6% to 7% per decade** |
- | | neuronal metabolic activity | **after age 40** (~30% drop by age 80) |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Neuraxial Anatomy** | • Calcified interspinous ligaments | • Difficult epidural/spinal placement |
- | | • Stenosis of intervertebral foramina| • Local anesthetic spreads higher; dose |
- | | • Decreased CSF volume and pressure | requirements **reduced by 20-40%** |
- +-----------------------+--------------------------------------+------------------------------------------+
NCE Clinical Rule — MAC Reduction Calculation: For every decade beyond 40 years of age, volatile anesthetic MAC decreases by 6.7 % 6.7\% 6.7% ( 0.67 % 0.67\% 0.67% per year).
- Baseline Sevoflurane MAC at 40 years = 2.0 % = 2.0\% = 2.0%
- At 80 years (4 decades older): Reduction = 4 × 6.7 % = 26.8 % = 4 \times 6.7\% = 26.8\% = 4 × 6.7% = 26.8%
Adjusted Sevoflurane MAC at 80 years ≈ 2.0 % × ( 1 − 0.268 ) ≈ 1.46 % \approx 2.0\% \times (1 - 0.268) \approx 1.46\% ≈ 2.0% × ( 1 − 0.268 ) ≈ 1.46%
4. Renal, Hepatic & Body Composition Pharmacokinetics +-------------------------------------------------------------------------+
- | GERIATRIC PHARMACOKINETIC SHIFTS |
- +-------------------------------------------------------------------------+
- | 1. Total Body Water (TBW) DECREASES (↓ 20-30%) |
- | → Smaller volume of distribution (Vd) for hydrophilic drugs |
- | → Higher initial peak plasma concentration (e.g., muscle relaxants) |
- | |
- | 2. Total Body Fat INCREASES (↑ 30-50%) |
- | → Larger volume of distribution (Vd) for lipophilic drugs |
- | → Prolonged elimination half-life (t1/2β) (e.g., diazepam, fentanyl) |
- | |
- | 3. Serum Albumin DECREASES (↓ 15-20%) |
- | → Higher free (unbound, active) fraction of acidic drugs (propofol, |
- | warfarin, phenytoin, diazepam) |
- | |
- | 4. Alpha-1-Acid Glycoprotein (AAG) INCREASES (or remains stable) |
- | → Increased binding / lower free fraction of basic drugs (lidocaine, |
- | bupivacaine, ropivacaine) |
- +-------------------------------------------------------------------------+
- Renal Elimination & The Serum Creatinine Pitfall
Renal Cortical Atrophy: Glomerular filtration rate (GFR) and renal blood flow decline at a rate of approximately 1 mL/min/year 1 \text{ mL/min/year} 1 mL/min/year after age 40 (or ≈ 8 − 10 % \approx 8 - 10\% ≈ 8 − 10% per decade).
The Serum Creatinine Trap: Because aging is accompanied by progressive skeletal muscle sarcopenia (decreased creatinine production), serum creatinine often remains completely normal ( 0.8 − 1.1 mg/dL 0.8 - 1.1 \text{ mg/dL} 0.8 − 1.1 mg/dL ) despite a 50 % 50\% 50% reduction in true GFR.
Creatinine Clearance Calculation (Cockcroft-Gault Equation): CrCl = ( 140 − Age ) × Weight (kg) 72 × Serum Creatinine (mg/dL) ( × 0.85 for females ) \text{CrCl} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Serum Creatinine (mg/dL)}} \quad (\times 0.85 \text{ for females}) CrCl = 72 × Serum Creatinine (mg/dL) ( 140 − Age ) × Weight (kg) ( × 0.85 for females )
Hydrophilic drugs eliminated via renal excretion (e.g., pancuronium, rocuronium metabolites, vecuronium, neostigmine, sugammadex, antibiotics) exhibit delayed clearance and prolonged duration of action.
Hepatic Clearance & Biotransformation
Total hepatic blood flow decreases by 30 − 40 % 30 - 40\% 30 − 40% with age due to decreased cardiac output and parenchymal atrophy.
Phase I Metabolism (CYP450 Oxidation, Reduction, Hydrolysis): Significantly impaired in elderly patients, prolonging the clearance of midazolam, lidocaine, alfentanil, and diazepam.
Phase II Metabolism (Conjugation: Glucuronidation, Sulfation, Acetylation): Relatively preserved in the elderly. Drugs metabolized primarily via Phase II conjugation (e.g., lorazepam, oxazepam, temazepam) do not accumulate active Phase I intermediates.
Pseudocholinesterase (Butyrylcholinesterase): Activity decreases by ≈ 25 % \approx 25\% ≈ 25% in elderly males, potentially prolonging succinylcholine and mivacurium duration slightly.
5. Postoperative Delirium (POD) vs. Postoperative Cognitive Dysfunction (POCD)
Perioperative neurocognitive disorders represent significant complications associated with increased morbidity, prolonged hospital stay, loss of functional independence, and elevated 1-year mortality. +---------------------------------------------------------------------------------------------------------+
- | POSTOPERATIVE DELIRIUM (POD) VS. COGNITIVE DYSFUNCTION (POCD) |
- +-----------------------+--------------------------------------+------------------------------------------+
- | Characteristic | Postoperative Delirium (POD) | Postoperative Cognitive Dysfunction (POCD|
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Clinical Definition**| Acute, fluctuating disturbance of | Subtle, persistent neurocognitive decline|
- | | attention, awareness, and cognition | in memory, executive function, attention |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Onset Timing** | **Acute (Postoperative Days 1 - 3)** | **Delayed / Insidious (Weeks to Months)**|
- | | Often peaks at night ("sundowning") | Evident after discharge |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Duration** | Hours to days (transient & reversible| Months to permanent |
- | | in most cases) | |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Diagnostic Tool** | **CAM-ICU** (Confusion Assessment | Formal, battery-style **Neuropsychometric|
- | | Method for the ICU) or 3D-CAM | Testing** (preop vs postop z-scores) |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Clinical Subtypes** | • Hyperactive (agitation, combative) | Subtle deficits in processing speed, |
- | | • **Hypoactive (lethargic, flat - | multitasking, recall, spatial awareness |
- | | MOST COMMON & OFTEN MISSED)** | |
- | | • Mixed (fluctuates between both) | |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Major Risk Factors**| Baseline dementia, age >70, severe | Advanced age, low baseline education, |
- | | pain, infection, sleep deprivation, | major cardiac surgery / CPB, cerebral |
- | | anticholinergic/sedative exposure | microemboli, prolonged inflammation |
+-----------------------+--------------------------------------+------------------------------------------+ [CAM-ICU DIAGNOSTIC ALGORITHM FOR DELIRIUM]
- Feature 1: Acute Onset or Fluctuating Course
- +
- Feature 2: Inattention
- |
- +-------------------+-------------------+
- | |
- v v
- Feature 3: Disorganized Feature 4: Altered Level of
- Thinking Consciousness
- | |
- +-------------------+-------------------+
- |
- v
- **DIAGNOSIS: POSITIVE DELIRIUM**
- (Requires: Feature 1 + Feature 2 AND [Feature 3 OR 4])
- 6. The Beers Criteria & Perioperative Neurotoxicity
The American Geriatrics Society (AGS) Beers Criteria identifies medications with unfavorable risk-to-benefit profiles in older adults due to high anticholinergic burden, CNS depression, or toxic metabolite accumulation. +---------------------------------------------------------------------------------------------------------+
- | PERIOPERATIVE BEERS CRITERIA HIGH-RISK DRUGS |
- +-----------------------+--------------------------------------+------------------------------------------+
- | Medication / Class | Adverse Mechanism in Geriatrics | Anesthetic Alternative |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Benzodiazepines** | • Profound sedation, ataxia, memory | • Multimodal opioid-sparing analgesia, |
- | (Midazolam, Diazepam) | impairment, 3-fold POD risk spike | reassurance, low-dose dexmedetomidine |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Tertiary Anticholin-| • Crosses blood-brain barrier (BBB), | • **Glycopyrrolate** (quaternary amine, |
- | ergics** (Scopol- | precipitates central anticholiner- | does not cross BBB, peripheral only) |
- | amine, Atropine) | gic syndrome and severe delirium | |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Diphenhydramine** | • Potent central muscarinic M₁ block | • 5-HT₃ antagonists (ondansetron), |
- | (H₁ Antihistamine) | causes acute confusion and delirium| dexamethasone for antiemesis/pruritus |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Meperidine** | • Active metabolite **normeperidine**| • Fentanyl, hydromorphone (low-dose), |
- | (Demerol) | causes CNS excitation, seizures | or IV acetaminophen; avoid meperidine |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Promethazine** | • Dopaminergic & anticholinergic blk | • Ondansetron, low-dose droperidol |
- +-----------------------+--------------------------------------+------------------------------------------+
- | **Ketorolac / NSAIDs**| • Acute renal failure, peptic ulcer, | • IV Acetaminophen, local infiltration, |
- | | and platelet dysfunction | selective regional nerve blocks |
- +-----------------------+--------------------------------------+------------------------------------------+
NCE Exam Trap — Reversal in the Geriatric Patient: When reversing non-depolarizing neuromuscular blockade in an 82-year-old with Neostigmine, pair it with Glycopyrrolate rather than Atropine. Glycopyrrolate is a quaternary ammonium compound that carries a permanent positive charge and cannot penetrate the blood-brain barrier, avoiding central anticholinergic syndrome and postoperative delirium. Furthermore, Sugammadex provides rapid, complete reversal without autonomic or cholinergic side effects, minimizing residual curarization in the elderly.